95 related articles for article (PubMed ID: 21036600)
1. Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis.
Sidi R; Pasello G; Opitz I; Soltermann A; Tutic M; Rehrauer H; Weder W; Stahel RA; Felley-Bosco E
Eur J Cancer; 2011 Jan; 47(2):326-32. PubMed ID: 21036600
[TBL] [Abstract][Full Text] [Related]
2. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
[TBL] [Abstract][Full Text] [Related]
4. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
5. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
Aoe K; Amatya VJ; Fujimoto N; Ohnuma K; Hosono O; Hiraki A; Fujii M; Yamada T; Dang NH; Takeshima Y; Inai K; Kishimoto T; Morimoto C
Clin Cancer Res; 2012 Mar; 18(5):1447-56. PubMed ID: 22261805
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
Ak G; Metintas M; Metintas S; Yildirim H; Ozkan R; Ozden H
Eur J Radiol; 2010 Apr; 74(1):130-5. PubMed ID: 19268516
[TBL] [Abstract][Full Text] [Related]
9. Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia.
Hasani A; Feeney K; Nowak A; Millward M
Asia Pac J Clin Oncol; 2010 Dec; 6(4):350-6. PubMed ID: 21114785
[TBL] [Abstract][Full Text] [Related]
10. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
Porta C; Zimatore M; Bonomi L; Imarisio I; Paglino C; Sartore-Bianchi A; Mutti L
Lung Cancer; 2005 Jun; 48(3):429-34. PubMed ID: 15893013
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
Matsuzaki Y; Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T
Ann Thorac Cardiovasc Surg; 2008 Jun; 14(3):161-5. PubMed ID: 18577894
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
13. High levels of uPA and PAI-1 predict a good response to anthracyclines.
Borstnar S; Sadikov A; Mozina B; Cufer T
Breast Cancer Res Treat; 2010 Jun; 121(3):615-24. PubMed ID: 20039121
[TBL] [Abstract][Full Text] [Related]
14. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.
Blayney JK; Ceresoli GL; Castagneto B; O'Brien ME; Hasan B; Sylvester R; Rudd R; Steele J; Busacca S; Porta C; Mutti L; O'Byrne KJ; Scullin P; Gaafar R; Baas P; Van Meerbeeck J; Fennell DA
Eur J Cancer; 2012 Nov; 48(16):2983-92. PubMed ID: 22704893
[TBL] [Abstract][Full Text] [Related]
15. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
16. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
Razak AR; Chatten KJ; Hughes AN
Lung Cancer; 2008 May; 60(2):294-7. PubMed ID: 17919769
[TBL] [Abstract][Full Text] [Related]
17. Trimodality therapy for malignant pleural mesothelioma.
Buduhan G; Menon S; Aye R; Louie B; Mehta V; Vallières E
Ann Thorac Surg; 2009 Sep; 88(3):870-5; discussion 876. PubMed ID: 19699914
[TBL] [Abstract][Full Text] [Related]
18. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Baratti D; Vaira M; Kusamura S; D'Amico S; Balestra MR; Cioppa T; Mingrone E; De Simone M; Deraco M
Eur J Surg Oncol; 2010 Nov; 36(11):1047-53. PubMed ID: 20832234
[TBL] [Abstract][Full Text] [Related]
19. Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma.
Marulli G; Rea F; Nicotra S; Favaretto AG; Perissinotto E; Chizzolini M; Vianello A; Braccioni F
Eur J Cardiothorac Surg; 2010 Jun; 37(6):1464-9. PubMed ID: 20153664
[TBL] [Abstract][Full Text] [Related]
20. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
